top of page

BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here

Jun 24
1 min read

President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page